Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -0.19% is 99% above its 5-year average of -16.98%, near the high end of its 5-year range (-70.95%–7.92%).
94.72% above its 12-month average of -3.60%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -10.77%.
EBITDA MARGIN
-0.19%
EBITDA MARGIN AVG TTM
-3.60%
EBITDA MARGIN AVG 3Y
-3.48%
EBITDA MARGIN AVG 5Y
-16.98%
EBITDA MARGIN AVG 10Y
-18.38%
EBITDA MARGIN AVG 15Y
-25.32%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+94.72%
CURRENT VS 3Y AVG
+94.53%
CURRENT VS 5Y AVG
+98.88%
CURRENT VS 10Y AVG
+98.97%
CURRENT VS 15Y AVG
+99.25%
CURRENT VS 20Y AVG
N/A
Market Cap
$159.14M
EBITDA Margin
-416.41%
TTM Avg
-228.13%
3Y Avg
-163.44%
5Y Avg
-116.60%
Market Cap
$159.80M
EBITDA Margin
4.91%
TTM Avg
4.91%
3Y Avg
4.91%
5Y Avg
4.91%
Market Cap
$162.04M
EBITDA Margin
-65.55%
TTM Avg
-49.11%
3Y Avg
-55.76%
5Y Avg
-50.22%
Market Cap
$153.79M
EBITDA Margin
-18.75%
TTM Avg
-31.07%
3Y Avg
-38.37%
5Y Avg
-40.79%
Market Cap
$153.58M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$165.27M
EBITDA Margin
-18889.15%
TTM Avg
-9445.90%
3Y Avg
-9445.90%
5Y Avg
-9445.90%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LifeMD, Inc. (LFMDP) | $159.22M | -0.19% | -3.60% | -3.48% | -16.98% |
| Coherus Oncology, Inc. (CHRS)vs › | $159.14M | -416.41% | -228.13% | -163.44% | -116.60% |
| PepGen Inc. (PEPG)vs › | $159.78M | N/A | N/A | N/A | N/A |
| Minerva Neurosciences, Inc. (NERV)vs › | $159.80M | 4.91% | 4.91% | 4.91% | 4.91% |
| Quanterix Corporation (QTRX)vs › | $162.04M | -65.55% | -49.11% | -55.76% | -50.22% |
| Inogen, Inc. (INGN)vs › | $156.22M | -2.74% | -4.58% | -13.60% | -7.28% |
| Neuronetics, Inc. (STIM)vs › | $153.79M | -18.75% | -31.07% | -38.37% | -40.79% |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $153.58M | N/A | N/A | N/A | N/A |
| Nkarta, Inc. (NKTX)vs › | $165.27M | -18889.15% | -9445.90% | -9445.90% | -9445.90% |
| OptimizeRx Corp. (OPRX)vs › | $165.32M | 14.98% | 2.40% | -11.30% | -6.96% |
Gross Margin
85.9%
EBITDA Margin
-0.2%
Operating Margin
-9.3%
Net Margin
-10.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -10.77% |
| 2026-03-31 | -13.82% |
| 2025-12-31 | 1.82% |
| 2025-09-30 | 1.70% |
| 2025-06-30 | 3.08% |
| 2025-03-31 | 7.92% |
| 2024-12-31 | 5.55% |
| 2024-09-30 | -2.70% |
| 2024-06-30 | -7.93% |
| 2024-03-31 | -9.22% |
| 2023-12-31 | -4.16% |
| 2023-09-30 | -7.34% |
| 2023-06-30 | -9.29% |
| 2023-03-31 | -4.48% |
| 2022-12-31 | -35.80% |
| 2022-09-30 | -18.86% |
| 2022-06-30 | -39.54% |
| 2022-03-31 | -43.30% |
| 2021-12-31 | -48.56% |
| 2021-09-30 | -50.00% |
| 2021-06-30 | -70.95% |
| 2021-03-31 | -64.90% |
| 2020-12-31 | -249.88% |
| 2020-09-30 | -185.58% |
| 2020-06-30 | -34.38% |
| 2020-03-31 | -38.42% |
| 2019-12-31 | -11.04% |
| 2019-09-30 | -28.46% |
| 2019-06-30 | -27.77% |
| 2019-03-31 | -17.76% |
| 2018-12-31 | -26.86% |
| 2018-09-30 | -16.32% |
| 2018-06-30 | -29.07% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 10.93% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 13.98% |
| 2017-03-31 | 6.32% |
| 2016-12-31 | -70.73% |
| 2016-09-30 | -14.21% |
| 2016-06-30 | -11.63% |
| 2016-03-31 | -5.74% |
| 2015-12-31 | -72.54% |
| 2015-09-30 | 11.86% |
| 2015-06-30 | -1.05% |
| 2015-03-31 | 7.66% |
| 2014-12-31 | -81.85% |
| 2014-09-30 | -71.74% |
| 2014-06-30 | -31.09% |
| 2014-03-31 | -84.91% |
| 2013-12-31 | -169.79% |
| 2013-09-30 | -163.11% |
| 2013-06-30 | -1.83% |
| 2013-03-31 | -24.56% |
| 2012-12-31 | -95.47% |
| 2012-09-30 | -98.31% |
| 2012-06-30 | -88.53% |
| 2012-03-31 | -12.17% |
